{"id":"pembrolizumab-us","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to PD-1, pembrolizumab releases the brakes on the immune system, allowing T cells to recognize and attack cancer cells. This mechanism is known as immune checkpoint inhibition. Pembrolizumab is designed to work in patients with tumors that have high levels of PD-L1, a protein that can bind to PD-1 and prevent T cell activation.","oneSentence":"Pembrolizumab is a monoclonal antibody that blocks the PD-1 receptor, preventing cancer cells from evading the immune system.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:48:33.462Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03546686","phase":"PHASE2","title":"Peri-Operative Immune Checkpoint Inhibition and Cryoablation in Women With Triple-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2019-11-12","conditions":"Breast Cancer","enrollment":51},{"nctId":"NCT06687369","phase":"PHASE3","title":"A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)","status":"RECRUITING","sponsor":"mAbxience Research S.L.","startDate":"2024-12-30","conditions":"Non Squamous Non Small Cell Lung Cancer","enrollment":726},{"nctId":"NCT07160335","phase":"PHASE1","title":"A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors","status":"RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-09-26","conditions":"Non-small Cell Lung Cancer, Melanoma, Renal Cell Carcinoma","enrollment":174},{"nctId":"NCT06153238","phase":"PHASE1","title":"A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sandoz","startDate":"2024-05-15","conditions":"Melanoma","enrollment":322},{"nctId":"NCT06311721","phase":"PHASE3","title":"A Study to Compare ABP 234 and Keytruda® (Pembrolizumab) in Participants With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2024-09-09","conditions":"Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer","enrollment":315},{"nctId":"NCT07180862","phase":"PHASE1","title":"A Study Evaluating BAT3306 Compared With Keytruda® in NSCLC Cancer Participants","status":"RECRUITING","sponsor":"Bio-Thera Solutions","startDate":"2025-10-14","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":140},{"nctId":"NCT06280196","phase":"PHASE3","title":"A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC","status":"TERMINATED","sponsor":"Bio-Thera Solutions","startDate":"2024-07-19","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":162},{"nctId":"NCT03319940","phase":"PHASE1","title":"Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amgen","startDate":"2017-12-26","conditions":"Small Cell Lung Carcinoma","enrollment":269},{"nctId":"NCT06268613","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Samsung Bioepis Co., Ltd.","startDate":"2024-01-16","conditions":"Non-small Cell Lung Cancer Stage II, Non-small Cell Lung Cancer Stage IIIA","enrollment":163},{"nctId":"NCT06345183","phase":"","title":"Real-World Outcomes of Nivolumab+Ipilimumab and Pembrolizumab+Lenvatinib Among US Advanced Renal Cell Carcinoma (aRCC) Patients","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2024-02-19","conditions":"Advanced Renal Cell Carcinoma (aRCC)","enrollment":327},{"nctId":"NCT07016399","phase":"PHASE2","title":"Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC","status":"RECRUITING","sponsor":"Vandana Abramson","startDate":"2025-09-09","conditions":"Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Triple-Negative Breast Carcinoma","enrollment":51},{"nctId":"NCT03108495","phase":"PHASE2","title":"Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma","status":"TERMINATED","sponsor":"Iovance Biotherapeutics, Inc.","startDate":"2017-06-22","conditions":"Cervical Carcinoma","enrollment":210},{"nctId":"NCT06847334","phase":"PHASE3","title":"A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2025-04-27","conditions":"Non-Squamous Non-Small Cell Lung Cancer","enrollment":772},{"nctId":"NCT02509507","phase":"PHASE1, PHASE2","title":"Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-02-05","conditions":"Hepatocellular Carcinoma, Liver Metastases, Cutaneous or Subcutaneous Lymph Node","enrollment":127},{"nctId":"NCT06173011","phase":"PHASE1","title":"A Study Comparing Pharmacokinetic and Safety of QL2107 and Keytruda® (Marketed in China and the United States) in Healthy Adults","status":"UNKNOWN","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2023-12-12","conditions":"Tumor","enrollment":168},{"nctId":"NCT05432622","phase":"","title":"A Study of Treatment Patterns and Outcomes in Participants With Stage IIIA Melanoma Receiving Adjuvant Systemic Therapy","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2019-12-19","conditions":"Melanoma","enrollment":95},{"nctId":"NCT02483247","phase":"PHASE1","title":"A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer","status":"COMPLETED","sponsor":"Sumitomo Pharma America, Inc.","startDate":"2015-09","conditions":"Cancer","enrollment":165},{"nctId":"NCT03588039","phase":"PHASE1","title":"Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Athenex, Inc.","startDate":"2018-10-25","conditions":"Solid Tumor","enrollment":34},{"nctId":"NCT03684785","phase":"PHASE1, PHASE2","title":"Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors","status":"TERMINATED","sponsor":"Exicure, Inc.","startDate":"2018-12-13","conditions":"Advanced or Metastatic Merkel Cell Carcinoma, Advanced or Metastatic Cutaneous Squamous Cell Carcinoma, Advanced or Metastatic Melanoma","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Keytruda®"],"phase":"phase_3","status":"active","brandName":"Pembrolizumab (US)","genericName":"Pembrolizumab (US)","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}